The Numbers Don’t Lie: Why the NIH Consistently Underfunds Research into Lyme Disease

An In-depth Interview with Kris Newby, Author of “Bitten”

 

“We need to let the NIH know that we’re watching them, and we want results.” 

– Kris Newby

 

Kris NewbyKris Newby, author of ‘Bitten,’ is investigating government spending on Lyme disease research, which is strongly influenced by the flawed original disease definition of Lyme disease. She summarizes the impact of the 2018 Tick-Borne Disease Working Group’s report, explains where research funding has and is currently being directed, and calls for money to be spent on better diagnostics and treatments for Lyme disease sufferers instead. Kris explores potential actions that Lyme patients can take to help direct the course of funding, such as communicating with Congress, supporting advocacy groups, and donating to research organizations.

The views and opinions expressed in this article are those of the interviewee and do not necessarily reflect the views or positions of Bay Area Lyme Foundation.

Kris Newby is watching our government, and watching quite closely. She has a lot to say about how government money is spent on a disease that, according to CDC estimates, infects almost 500,000 people annually in the US, causing untold pain, suffering, loss of livelihood, and, in extreme cases, severe mental illness, including suicidal and homicidal events.

Of course, we are talking about Lyme disease—the pariah of infection-associated chronic conditions.

Bay Area Lyme Foundation Opens Applications for 2025 Emerging Leader Award and Research Grant

ELA Award 2025

FOR IMMEDIATE RELEASE 

Bay Area Lyme Foundation Opens Applications for 2025 Emerging Leader Award and Research Grant

In its tenth year, the annual grant encourages novel approaches to revolutionizing diagnosis and treatment of tick-borne diseases

PORTOLA VALLEY, Calif., October 31, 2024 – Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., invites innovative researchers from academia and the private sector to apply for the 2025 Emerging Leader Awards (ELA). These awards recognize those advancing novel approaches in Lyme disease diagnostics and treatments, while embodying the future of Lyme disease research leadership. This year, in its tenth anniversary, Bay Area Lyme Foundation’s ELA will present two $150,000 awards for researchers who are at the post-doctoral level through associate professor level or equivalent.

While applicants must have a defined scientific approach to advancing diagnostics and/or therapeutics for Lyme disease, the grants are open to researchers from other therapeutic areas in addition to those who have previously investigated Lyme disease. Applications will be accepted through March 7, 2025 at 11:59pm, Pacific Time. The full criteria and application for this award can be found at www.bayarealyme.org/our-research/emerging-leader-award/.

“The global impact of both acute and chronic infections has never been more apparent, and tackling an infectious disease as complex as Lyme requires innovative approaches and concerted efforts to drive progress in diagnostics and treatment,” said Wendy Adams, research grant director Bay Area Lyme Foundation. “Our goal with the Emerging Leader Award is to inspire ambitious and creative scientists to take on the challenge of advancing accurate diagnostics and effective therapeutics for various stages of tick-borne diseases.”

Pathogens & Persistence: The Chronic Disease Drivers

Ticktective™ with Dana Parish

Dr. Steven Phillips

Steven E. Phillips, MD, is a Yale-trained expert on zoonotic infections and coauthor of the book CHRONIC. He specializes in treating medicine’s most complex cases, which include Lyme & other vector-borne disease and Long COVID. Additionally, he has served as an expert for the states of CT, NY, RI, and VT, providing testimony during their respective public hearings, which resulted in changes to existing healthcare laws. Dr. Phillips has been a longstanding public face of the Lyme pandemic. He is currently spearheading a drug development effort to bring the public a durable, effective treatment for some of these infections, which will hopefully change how we treat a range of rheumatologic and neurologic illnesses. Dr. Phillips also sits on the Bay Area Lyme Foundation’s scientific advisory board.

Toxic Load: Healing from Tick-borne Disease and Autoimmune Illness 

Jill Carnahan, MD

BAL “Quick Bites” Series

 

“If you have an autoimmune disease, our allopathic system does not have great answers that are solution-based or root cause-based to chronic complex illness.”

– Jill Carnahan, MD

In this edition of our Ticktective video and podcast series, Dana Parish sits down with Jill Carnahan, MD, a functional medicine doctor specializing in Lyme disease, tick-borne illnesses, mold toxicity, and other complex chronic health issues. Carnahan discusses her background growing up on a farm and how it influenced her approach to medicine. She shares her experience being diagnosed with breast cancer and the potential environmental factors, such as atrazine, that may have contributed to it. Carnahan talks about her cancer treatment and her belief in finding and addressing root causes in medicine. She then discusses her expertise in Lyme and tick-borne diseases, explaining how she evaluates and treats these conditions. She emphasizes the need for a clinical diagnosis of Lyme disease due to the limitations of mainstream tests. Carnahan also sheds light on the connection between mold exposure and chronic illness, including dementia and psychiatric disorders. She provides insights into testing, detoxification, and treatment strategies for mold-related illnesses. The interview concludes with information about connecting with Dr. Carnahan’s clinic, her book, and her documentary.

Understanding Infection-associated Chronic Illness: How the Immune System Responds to Persistent Infection

Distinguished Speaker Series with Michal Tal, PhD

Distinguished Speaker Series Transcript

 

Mihal Tal, PhD“I want to leave you with hope. I think we’re going to be unstoppable because I think that these are solvable problems. These are answerable questions. I think that there are already a lot of existing tools in immunology that just need to be brought into the fight, and we can change this.”

– Michal Caspi Tal, PhD

Michal Caspi Tal: In the chronic illness world, I think that there is something about hope with a capital ‘H’ that is precious. I think it always has to be. I want to talk a little bit about what my lab is doing, where I think we could go in the future and the hope that I have for how we move forward, how we solve this, and how we change this for those who come after us. So, I’ll tell you a little bit about some of the recent things that have come out of the lab, what the lab is working on now, and where we want to go. 

New Study Shows How Borrelia burgdorferi Evades the Immune System

Recently, we published a study in collaboration with Hanna Ollila’s lab where we compared people who’ve had Lyme and have had a diagnosis of Lyme versus people who’ve never had a diagnosis of Lyme. We found a genetic difference in a sweat protein that nobody—including me—had ever thought about before. We tested it against the bacteria in our lab, and we saw that it had a huge effect; we tested it in mice, and it had a huge effect. So that’s really exciting. We had another paper that came online yesterday that is one of these last papers from my postdoctoral work over at Stanford, where we actually managed to figure out some of how Borrelia burgdorferi, the bacteria that causes Lyme, manages to evade immune clearance. 

Michal Tal, PhDAny respectable pathogen that can establish a persistent infection needs to figure out your immune system to the point that it can evade it. The fact that it has persisted means that it was able to evade your immune clearance. And so, I got to that from a very interesting direction working on immune regulation, trying to understand these brakes on the immune response and how they impact the response to infection. The immune system has the power to kill you and obviously, nobody has any incentive for that to happen. So, there are a lot of mechanisms in place to put brakes on the immune system and reign it in. One of the huge developments in cancer over the last two decades has been reevaluating the question: can we take those brakes off? So in my postdoc, I was studying a particular checkpoint where this was turning into an exciting immuno-oncology target, and I said, ‘I want to look at how this checkpoint is used in infection.’ I realized that this checkpoint was being used to help you survive an acute infection, but created a vulnerability for pathogens to evade immune clearance and establish chronic infection much like it allows cancer cells to evade immune clearance. In an amazing collaboration with Irv Weissman, Balyn Zaro, and Jenifer Coburn we realized that the bacteria that cause Lyme disease manipulate this brake and that’s how I became fascinated with Lyme.  But I also became concerned about turning off this brake in cancer patients because I was concerned about what would happen if you used this on cancer patients during an active infection. Indeed, the clinical trials on this drug were ended due to increased death from infection, and I wish it hadn’t been tested during a worldwide pandemic.

The Toxic Truth: Mold, Lyme, and Helping Gwyneth Paltrow Get Well

Ticktective Podcasts

Mike Rubino

Michael is an air quality expert, author, and founder of HomeCleanse, a go-to source for information, services, and products to create healthier living through cleaner indoor air. A specialist in working with people who are immunocompromised or have acute and sustained reactions to mold exposure, Michael’s scientific understanding has enabled him to create change, via alternative remediation.

Unlocking the Mysteries of Tick-borne Infections: Lyme Disease Biobank’s Tissue Collection Program Drives Research Momentum

Kirsten Stein and the Lyme Disease Biobank

BAL Leading the Way Series

 

“My family knows that after I die, my tissues will be donated to Lyme Disease Biobank to provide researchers with the vital material they need to solve this horrible disease. I urge anyone with chronic/persistent Lyme to register with NDRI today. Let’s end this suffering together.” 

-Kirsten Stein, Lyme Advocate

Lyme Disease Biobank®, led by Liz Horn, PhD, MBI, is central to Bay Area Lyme Foundation’s 10-year search for answers to Lyme’s most intractable questions and is the most important program in the Foundation’s mission to make Lyme disease easy to diagnose and simple to cure. 

The original Lyme Disease Biobank sample collection launched in 2014 focused on obtaining blood, urine, and serum samples from patients with early/acute Lyme disease. Once this program had been fully established, the Lyme Disease Biobank team explored adding tissue samples to the Biobank. Tissue samples could help researchers expand their investigations beyond the early stage of infection into how chronic/persistent Lyme and other tick-borne diseases impact the central nervous system, joints, and organs of Lyme patients. 

With the tissue bank objectives defined, the Biobank connected with specialist organizations to provide the critical support needed to support sample collection and make the development of a tissue bank a reality.

Post-Mortem Tissue Collection Planning

NDRILyme Disease Biobank established a key partnership with the nonprofit National Disease Research Interchange (NDRI) to provide logistics for post-mortem tissue collection for the new tissue program. The Biobank also partnered with MyLymeData.org, allowing Lyme patients registered with the Biobank to link their MyLymeData profile to their tissue donation if desired. Bringing these two resources together provides for the organizing and recovery of post-mortem (after death) tissue. It ensures samples include redacted (removes identifying information) detailed patient medical histories—an important nuance for Lyme disease researchers. 

“Although it is an emotional and difficult idea for anyone to plan to donate parts of their body to science after they have died, we believe that this decision is an important way for Lyme patients to change the course of Lyme disease research. Having access to tissues from the brain, heart, joints, and central nervous system of Lyme patients allows researchers to prove unequivocally that Lyme is present in tissue and contributes to patient suffering,” explains Linda Giampa, Executive Director, Bay Area Lyme Foundation and board member of Lyme Disease Biobank.

Matt Kaeberlein, Rapamycin, and the Dog Aging Project: What Animals Can Teach Us About Aging Better

Matt Kaeberlein

BAL “Quick Bites” Series

 

In scientific exploration, few fields captivate the imagination quite like the study of aging. It’s a universal process affecting all living beings, yet its mechanisms remain elusive and its implications profound. Recently, a spotlight has been cast on aging research through initiatives like the Dog Aging Project, spearheaded by Dr. Matt Kaeberlein. This ambitious endeavor aims not only to understand the biological underpinnings of aging in dogs but also to glean insights that could potentially enhance human longevity. At the forefront of this research is rapamycin, a drug with promising anti-aging properties. In our latest Ticktective interview, Dana Parish delves into the intricacies of this groundbreaking project with Dr. Kaeberlein and learns what animals, particularly dogs, can teach us about aging better.

“Investing in research on aging and companion animal health can pave the way for longer, healthier lives for both humans and animals.”

– Matt Kaeberlein

Toxic Load: Healing from Tick-borne Disease, Long Covid, Mold, & Bad Food

Ticktective Podcasts

Jill Carnahan, MD

Jill Carnahan, MD, is a functional medicine doctor with a huge media presence, board-certified in Family Medicine and Integrative Holistic Medicine. She is the Medical Director of Flatiron Functional Medicine, a sought-after practice with a broad range of clinical services. As a survivor of breast cancer, Crohn’s disease, and toxic mold illness she brings a unique perspective to treating patients in the midst of complex and chronic illness. Her clinic specializes in searching for the underlying triggers that contribute to illness through cutting-edge lab testing and tailoring the intervention to specific needs.

Featured in People magazine, Shape, Parade, Forbes, MindBodyGreen, First for Women, Townsend Newsletter, and The Huffington Post as well as seen on NBC News and Health segments with Joan Lunden, Dr. Jill is a media must-have. Her YouTube channel and podcast features live interviews with the healthcare world’s most respected names.

Bay Area Lyme Foundation Selects National Winner of the 2024 Emerging Leader Award for Research of Combination Therapies to Treat Chronic Lyme Disease

Trever Smith, PhD winner of Emerging Leader Award

FOR IMMEDIATE RELEASE

 

Bay Area Lyme Foundation Selects National Winner of the 2024 Emerging Leader Award for Research of Combination Therapies to Treat Chronic Lyme Disease

Winner Trever Smith, of Tufts University, will collect novel therapeutic data to develop a first-of-its-kind drug interaction compendium for Lyme Disease

PORTOLA VALLEY, Calif., August 1, 2024—Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the recipient of the 2024 Emerging Leader Award (ELA), which is designed to support new and innovative research and aims to attract aspiring new scientific talent to the field of Lyme. This year’s winner, Trever Smith, PhD, Research Assistant Professor of Molecular Biology and Microbiology at Tufts University School of Medicine, will receive $150,000 for his work to identify precise treatment combinations that more effectively target persistent Borrelia burgdorferi (Bb) infection in persistent Lyme patients. For this research, Dr. Smith intends to develop a first-of-its-kind drug interaction compendium to help prioritize the most effective combinations for testing in pre-clinical models of Lyme disease. To do so, Dr. Smith will leverage techniques he and other researchers use to identify effective drug combinations against other infectious diseases, such as tuberculosis, and translate them for Bb. Due to the difficulty in diagnosing and treating Lyme disease, it is estimated that over two million patients currently suffer from the debilitating later-stage symptoms of persistent Lyme in the US, and there are currently no FDA-approved treatments for the persistent symptoms of Lyme disease.

“While combination therapies to treat chronic Lyme have shown promise in early research and are widely used with success in other disease areas, the vast majority of chronic Lyme patients are not able to benefit from combination therapies,” said Wendy Adams, research grant director, Bay Area Lyme Foundation. “Dr. Smith’s research aims to change this, as it builds on his previous research success in tuberculosis to bring the hope of combination therapies for Lyme to the forefront and seeks to give clinicians and researchers a better understanding of the advantages of combining current FDA-approved treatments in Lyme disease.”